Plasma protease C1-inhibitor (C1-INH) treatment products are biologics used for preventing attacks in patients with hereditary angioedema (HAE), a rare genetic disorder caused by insufficient levels of functional C1 inhibitor protein in blood. The recombinant and plasma-derived C1-INH concentrates help manage swelling and pain associated with HAE attacks by inhibiting proteins of the complement and contact systems.
The global plasma protease C1-inhibitor treatment market is estimated ... Read more
